Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Nubytide in Alzheimer Disease: NCT07568041 Clinical Landscape Report 2026
18 September 2026
NCT07568041 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Etomidate in Ovarian Cancer: ISRCTN10813814 Clinical Landscape Report 2026
18 September 2026
ISRCTN10813814 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TCX-102 in Relapsing acute myeloid leukemia: NCT07566585 Clinical Landscape Report 2026
18 September 2026
NCT07566585 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Flortaucipir F-18 in Alzheimer Disease: NCT07580703 Clinical Landscape Report 2026
18 September 2026
NCT07580703 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sirolimus in Multiple Myeloma: NCT07581704 Clinical Landscape Report 2026
18 September 2026
NCT07581704 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tofacitinib Citrate in Plaque psoriasis: NCT07581418 Clinical Landscape Report 2026
18 September 2026
NCT07581418 clinical landscape for Plaque psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ginkgo Biloba leaves Extract in Alzheimer Disease: NCT07579689 Clinical Landscape Report 2026
18 September 2026
NCT07579689 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD19-CAR.p40-T Cells (Shenzhen University General Hospital) in Acute Myeloid Leukemia: NCT07584889 Clinical Landscape Report 2026
18 September 2026
NCT07584889 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GD2/mesothelin Dual-Target CAR-NK(Beijing Biotech) in Primary peritoneal carcinoma: NCT07589543 Clinical Landscape Report 2026
18 September 2026
NCT07589543 clinical landscape for Primary peritoneal carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
XmAb-541 in Ovarian Cancer: NCT07593092 Clinical Landscape Report 2026
18 September 2026
NCT07593092 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Recurrent Acute Leukemia: NCT07583303 Clinical Landscape Report 2026
18 September 2026
NCT07583303 clinical landscape for Recurrent Acute Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Myeloid Tumor: NCT07591649 Clinical Landscape Report 2026
18 September 2026
NCT07591649 clinical landscape for Myeloid Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.